Bedoradrine

Bedoradrine
Clinical data
Other namesKUR-1246; MN-221
Identifiers
  • 2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H32N2O5
Molar mass428.529 g·mol−1
3D model (JSmol)
  • CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1
  • InChI=1S/C24H32N2O5/c1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27/h4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3/t20-,23-/m0/s1
  • Key:OANCEOSLKSTLTA-REWPJTCUSA-N

Bedoradrine (INNTooltip International Nonproprietary Name; developmental code names KUR-1246, MN-221) is a sympathomimetic and bronchodilator medication that was developed for the treatment of preterm labor, asthma, and chronic obstructive pulmonary disease (COPD) but was never marketed.[1][2][3] It acts as an ultra-selective long-acting β2-adrenergic receptor agonist.[1][2] The drug was intended for intravenous administration.[1][2]

See also

References

  1. ^ a b c Antoniu S (August 2014). "Bedoradrine for treating asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 23 (8): 1149–1156. doi:10.1517/13543784.2014.928284. PMID 24938936.
  2. ^ a b c Cazzola M, Calzetta L, Matera MG (May 2011). "β(2) -adrenoceptor agonists: current and future direction". Br J Pharmacol. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864. PMID 21232045.
  3. ^ "Bedoradrine: Uses, Interactions, Mechanism of Action". DrugBank Online. 18 November 2007. Retrieved 1 September 2024.
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.